Entrada Therapeutics, Inc. (TRDA) Tops Q3 EPS by 176c

Entrada Therapeutics, Inc. (NASDAQ: TRDA) reported Q3 EPS of $1.02, $1.76 better than the analyst estimate of ($0.74). Revenue for the quarter came in at $43.74 million versus the consensus estimate of $9.6 million.

For earnings history and earnings-related data on Entrada Therapeutics, Inc. (TRDA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery